title: Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
abstract: OBJECTIVE
  Gemcitabine (GEM) and vinorelbine (VNR) have demonstrated activity as a first-line treatment in elderly patients with advanced non-small-cell lung cancer (NSCLC). We conducted a multicenter phase II trial to evaluate the efficacy and toxicity of bi-weekly administration of GEM plus VNR in elderly patients with advanced NSCLC.
  
  
  METHODS
  Forty-six chemotherapy-naive elderly (age: >or=70 years) NSCLC patients were enrolled. Patients were eligible if they had histologically or cytologically confirmed unresectable NSCLC with measurable and/or assessable disease. Patients received GEM (1000 mg/m2) and VNR (25 mg/m2) every 2 weeks.
  
  
  RESULTS
  The objective response rate of this treatment was 22.7% (95% confidence interval (CI), 10.3-35.1%), median survival time was 310 days, and median time to progression was 133 days. The one-year survival rate was 40.9% (95% CI, 26.3-55.4%), and most adverse events were mild. Only three (6.8%) patients needed to omit GEM because of grade 4 neutropenia or due to physician judgment. No patients suffered treatment-related death.
  
  
  CONCLUSIONS
  Bi-weekly administration of GEM plus VNR in elderly patients was an effective, feasible and well-tolerated treatment schedule.
authors.affiliation: Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa 920-8641, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Araya
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kasahara
authors.forename: Hideharu
authors.initials: H
authors.lastname: Kimura
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Shibata
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kita
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shirasaki
authors.forename: Johsuke
authors.initials: J
authors.lastname: Hara
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Yoshimi
authors.forename: Takashi
authors.initials: T
authors.lastname: Sone
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Oribe
authors.forename: Kouichi
authors.initials: K
authors.lastname: Nobata
authors.forename: Kouichi
authors.initials: K
authors.lastname: Nishi
authors.forename: Masaki
authors.initials: M
authors.lastname: Fujimura
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D012189:Retrospective Studies; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D014747:Vinblastine; D012264:Ribonucleotide Reductases; D000077235:Vinorelbine; D000093542:Gemcitabine